New Orally Administrable Peptide for Treatment of Diabetes
Diabetes is a major health concern that caused 1.5 million deaths before the age of 70 in 2019. This number continues to rise.
Current glucagon-like peptide 1 (GLP-1)-based anti-diabetic peptides are effective at normalising hyperglycemia and preventing diabetic complications, but they are costly. This has implications for both public policy and social justice in middle-income and low-income countries. New affordable orally administrable peptides are urgently needed to treat diabetes. This means discovering and characterising new metabolic factors and exploring their potential for treating obesity-related medical complications.
This research identified a novel gastric hormone CYSTM1 that can be used to treat both type II and I diabetes by oral administration. As CYSTM1 has high bioavailability, it does not require chemical modification, which preserves its potency and specificity. This reduces potentially toxic bio-accumulation risks and drug development costs.
This discovery offers hope for an affordable and effective treatment for diabetes.
Current glucagon-like peptide 1 (GLP-1)-based anti-diabetic peptides are effective at normalising hyperglycemia and preventing diabetic complications, but they are costly. This has implications for both public policy and social justice in middle-income and low-income countries. New affordable orally administrable peptides are urgently needed to treat diabetes. This means discovering and characterising new metabolic factors and exploring their potential for treating obesity-related medical complications.
This research identified a novel gastric hormone CYSTM1 that can be used to treat both type II and I diabetes by oral administration. As CYSTM1 has high bioavailability, it does not require chemical modification, which preserves its potency and specificity. This reduces potentially toxic bio-accumulation risks and drug development costs.
This discovery offers hope for an affordable and effective treatment for diabetes.
